NovoCure Limited Increase (Decrease) in Accounts Payable and Accrued Liabilities
NovoCure Limited (NVCR) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of $2.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-07-23
- NovoCure Limited increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $2.80M, a 32.75% increase year-over-year.
- NovoCure Limited increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$5.12M.
- NovoCure Limited increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $8.44M, a 58.52% decline year-over-year.
- NovoCure Limited increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $24.83M, a 233.20% increase year-over-year.
- NovoCure Limited increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $19.11M, a 28.50% increase from fiscal 2023.
- NovoCure Limited increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $14.87M, a 4.29% increase from fiscal 2022.
- NovoCure Limited increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $14.26M, a 48.67% decline from fiscal 2021.
- NovoCure Limited increase (decrease) in accounts payable and accrued liabilities for fiscal 2021 was $27.78M, a 9.06% increase from fiscal 2020.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.80M 10-Q · filed 2026-07-23 | -$2.32M 10-Q · filed 2026-07-23 | $6.12M derived: sum of 3 quarters · filed 2026-07-23 | $30.95M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | -$5.12M 10-Q · filed 2026-04-30 | $3.32M derived: sum of 2 quarters · filed 2026-07-23 | $28.15M derived: sum of 3 quarters · filed 2026-07-23 | $30.26M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $8.44M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-07-23 | $33.27M derived: sum of 2 quarters · filed 2026-07-23 | $35.38M derived: sum of 3 quarters · filed 2026-07-23 | $18.96M 10-Q · filed 2026-07-23 |
| 2025-09-30 | $24.83M 10-Q · filed 2025-10-30 | $26.94M derived: sum of 2 quarters · filed 2026-07-23 | $10.52M 10-Q · filed 2025-10-30 | $30.87M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $2.11M 10-Q · filed 2026-07-23 | -$14.31M 10-Q · filed 2026-07-23 | $6.04M derived: sum of 3 quarters · filed 2026-07-23 | $13.49M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | -$16.42M 10-Q · filed 2026-04-30 | $3.93M derived: sum of 2 quarters · filed 2026-04-30 | $11.38M derived: sum of 3 quarters · filed 2026-04-30 | $20.93M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $20.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $27.80M derived: sum of 2 quarters · filed 2026-02-26 | $37.35M derived: sum of 3 quarters · filed 2026-02-26 | $19.11M 10-K · filed 2026-02-26 |
| 2024-09-30 | $7.45M 10-Q · filed 2025-10-30 | $17.00M derived: sum of 2 quarters · filed 2025-10-30 | -$1.25M 10-Q · filed 2025-10-30 | $17.62M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $9.55M 10-Q · filed 2025-07-24 | -$8.70M 10-Q · filed 2025-07-24 | $10.16M derived: sum of 3 quarters · filed 2026-02-26 | $16.43M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$18.25M 10-Q · filed 2025-04-24 | $616.00K derived: sum of 2 quarters · filed 2026-02-26 | $6.88M derived: sum of 3 quarters · filed 2026-02-26 | $7.09M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $18.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $25.13M derived: sum of 2 quarters · filed 2026-02-26 | $25.33M derived: sum of 3 quarters · filed 2026-02-26 | $14.87M 10-K · filed 2026-02-26 |
| 2023-09-30 | $6.26M 10-Q · filed 2024-10-30 | $6.47M derived: sum of 2 quarters · filed 2024-10-30 | -$3.99M 10-Q · filed 2024-10-30 | $12.16M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $207.00K 10-Q · filed 2024-07-25 | -$10.26M 10-Q · filed 2024-07-25 | $5.89M derived: sum of 3 quarters · filed 2025-02-27 | $11.16M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$10.46M 10-Q · filed 2024-05-02 | $5.69M derived: sum of 2 quarters · filed 2025-02-27 | $10.95M derived: sum of 3 quarters · filed 2025-02-27 | $18.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $16.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $21.42M derived: sum of 2 quarters · filed 2025-02-27 | $29.07M derived: sum of 3 quarters · filed 2025-02-27 | $14.26M 10-K · filed 2025-02-27 |
| 2022-09-30 | $5.26M 10-Q · filed 2023-10-26 | $12.91M derived: sum of 2 quarters · filed 2023-10-26 | -$1.90M 10-Q · filed 2023-10-26 | $15.26M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $7.65M 10-Q · filed 2023-07-27 | -$7.16M 10-Q · filed 2023-07-27 | $9.99M derived: sum of 3 quarters · filed 2024-02-22 | $18.12M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$14.81M 10-Q · filed 2023-05-04 | $2.35M derived: sum of 2 quarters · filed 2024-02-22 | $10.47M derived: sum of 3 quarters · filed 2024-02-22 | $15.59M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $17.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $25.28M derived: sum of 2 quarters · filed 2024-02-22 | $30.40M derived: sum of 3 quarters · filed 2024-02-22 | $27.78M 10-K · filed 2024-02-22 |
| 2021-09-30 | $8.13M 10-Q · filed 2022-10-27 | $13.25M derived: sum of 2 quarters · filed 2022-10-27 | $10.62M 10-Q · filed 2022-10-27 | $28.12M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $5.12M 10-Q · filed 2022-07-28 | $2.50M 10-Q · filed 2022-07-28 | $19.99M derived: sum of 3 quarters · filed 2023-02-23 | $29.90M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | -$2.63M 10-Q · filed 2022-04-28 | $14.87M derived: sum of 2 quarters · filed 2023-02-23 | $24.78M derived: sum of 3 quarters · filed 2023-02-23 | $25.18M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $17.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $27.40M derived: sum of 2 quarters · filed 2023-02-23 | $27.81M derived: sum of 3 quarters · filed 2023-02-23 | $25.47M 10-K · filed 2023-02-23 |
| 2020-09-30 | $9.91M 10-Q · filed 2021-10-28 | $10.31M derived: sum of 2 quarters · filed 2021-10-28 | $7.97M 10-Q · filed 2021-10-28 | $13.96M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $405.00K 10-Q · filed 2021-07-29 | -$1.93M 10-Q · filed 2021-07-29 | $4.05M derived: sum of 3 quarters · filed 2022-02-24 | $10.48M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | -$2.34M 10-Q · filed 2021-04-29 | $3.64M derived: sum of 2 quarters · filed 2022-02-24 | $10.07M derived: sum of 3 quarters · filed 2022-02-24 | $12.30M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $12.41M derived: sum of 2 quarters · filed 2022-02-24 | $14.64M derived: sum of 3 quarters · filed 2022-02-24 | $16.88M 10-K · filed 2022-02-24 |
| 2019-09-30 | $6.43M 10-Q · filed 2020-10-29 | $8.66M derived: sum of 2 quarters · filed 2020-10-29 | $10.90M 10-Q · filed 2020-10-29 | $27.38M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $2.22M 10-Q/A · filed 2020-10-02 | $4.47M 10-Q/A · filed 2020-10-02 | $20.94M derived: sum of 3 quarters · filed 2021-02-25 | $23.78M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $2.25M 10-Q/A · filed 2020-10-02 | $18.72M derived: sum of 2 quarters · filed 2021-02-25 | $21.56M derived: sum of 3 quarters · filed 2021-02-25 | |
| 2018-12-31 | $16.47M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $19.31M derived: sum of 2 quarters · filed 2021-02-25 | $13.71M 10-K · filed 2021-02-25 | |
| 2018-09-30 | $2.84M 10-Q · filed 2019-10-31 | -$2.76M 10-Q · filed 2019-10-31 | ||
| 2017-12-31 | $13.31M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| Inspire Medical Systems, Inc. (INSP) | United States | $1.990B | 9.55 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |